AFM
ONCY

Anson Funds Management’s Oncolytics Biotech ONCY Stock Holding History

Anson Funds Management’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,814,299
Closed -$5.15M – 195
2023
Q4 		$5.15M Sell
3,814,299
-1,487,737
-28% -$2.33M 0.64% 33
2023
Q3 		$11.6M Buy
+5,302,036
New +$13M 2.33% 11

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Anson Funds Management's ONCY Position: Q1 2024 in Review

Anson Funds Management sold out of Oncolytics Biotech (ONCY) in Q1 2024, closing a stake of 3,814,299 shares — an estimated $5.15M sold.

Anson Funds Management first reported a position in ONCY in Q3 2023 and held it in 2 quarters. The position peaked at $11.6M in Q3 2023. 36 funds tracked by Wall St. Rank hold ONCY as of Q1 2024.

  • Anson Funds Management reported no remaining Oncolytics Biotech position as of Q1 2024 after selling out during the quarter.
  • Anson Funds Management sold 3,814,299 Oncolytics Biotech shares in Q1 2024, an estimated $5.15M.
  • Anson Funds Management first reported a position in Oncolytics Biotech in Q3 2023 and held it in 2 quarters.
  • Anson Funds Management's Oncolytics Biotech position peaked at $11.6M in Q3 2023.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2024.

Based on Anson Funds Management's 13F filing for Q1 2024, filed 14 May 2024.